The CAR-T cancer therapy called Carvykti, made by Johnson & Johnson and Legend Biotech, reduced the risk of relapse by 74% compared to standard treatment in patients with multiple myeloma, according to results from a Phase 3 study that leaked online Tuesday night.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.